Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine

Cancer

Volumn 106, Issue 6, 2006, Pages 1395-1401

  Hartman, Annelies ^a   Van Bos, Cor Den ^b   Stijnen, Theo ^c   Pieters, Rob ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Late effects; Motor performance; Polyneuropathy; Vincristine

Indexed keywords

CORTICOSTEROID; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LYMPHOMA; CHILDHOOD CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG PULSE THERAPY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MESENCHYMOMA; MOTOR PERFORMANCE; NEPHROBLASTOMA; NONHODGKIN LYMPHOMA; POLYNEUROPATHY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOMA, B-CELL; MALE; MESODERM; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; PSYCHOMOTOR PERFORMANCE; VINCRISTINE; WILMS TUMOR;

EID: 33644837042     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21706     Document Type: Article

References (35)

1. Riccardi R, Lasorella A, Mastrangelo R. Principles of cancer therapy in children. In: Voute P, Kalifa C, Barrett A, editors. Cancer in children: clinical management, 4th ed. Oxford: Oxford University Press, 1998:44-59.
2. Gidding CE, Kellie SJ, Kamps WA, de Graaf SS. Vincristine revisited. Crit Rev Oncol Hematol. 1999;29:267-287.
3. Eiser C, Lansdown R. Retrospective study of intellectual development in children treated for acute lymphoblastic leukaemia. Arch Dis Child. 1977;52:525-529.
4. Harten G, Stephani U, Langermann H-J, Riehm H, Hanefeld F. Slight impairment of psychomotor skills in children after treatment of acute lymphoblastic leukemia. Eur J Pediatr. 1984;142:189-197.
5. Vainionpaa L. Clinical neurological findings of children with acute lymphoblastic leukaemia at diagnosis and during treatment. Eur J Pediatr. 1993;152:115-119.
6. Reinders-Messelink HA, Schoemaker MM, Hofte M, et al. Fine motor and handwriting problems after treatment for childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1996;27:551-555.
7. Wright MJ, Halton JM, Barr RD. Limitation of ankle range of motion in survivors of acute lymphoblastic leukemia: a cross-sectional study. Med Pediatr Oncol. 1999;32:279-282.
8. Wright MJ, Halton JM, Martin RF, Barr RD. Long-term gross motor performance following treatment for acute lymphoblastic leukemia. Med Pediatr Oncol. 1998;31:86-90.
9. DeAngelis LM, Gnecco C, Taylor L, Warrell RP Jr. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma. Cancer. 1991;67:2241-2246.
10. Haim N, Epelbaum R, Ben-Shahar M, Yarnitsky D, Simri W, Robinson E. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer. 1994;73:2515-2519.
11. Kamps WA, Bokkerink JPM, Hakvoort-Cammel FGAJ, et al. Results of the DCLSG-study ALL8 (1991-1997): BFM oriented treatment without cranial irradiation (CI) and comparing conventional oral and high-doses intravenous 6-mercaptopurine [abstract]. Med Pediatr Oncol. 1999;33:169.
12. Veerman AJ, Hahlen K, Kamps WA, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol. 1996;14:911-918.
13. D'Angio GJ. SIOP (International Society of Paediatric Oncology) and the management of Wilms' tumor. J Clin Oncol. 1983;1:595-596.
14. Graf N, Tournade MF, de Kraker J. The role of preoperative chemotherapy in the management of Wilms' tumor. The SIOP studies. International Society of Pediatric Oncology. Urol Clin North Am. 2000;27:443-454.
15. Henderson S, Sugden D. Movement assessment battery for children. Sidcup, UK: Psychological Corporation, 1992.
16. Smits-Engelsman BC. Movement assessment battery for children; Nederlandse bewerking. Lisse, Netherlands: Swets & Zeitlinger, 1998.
17. Croce RV, Horvat M, McCarthy E. Reliability and concurrent validity of the movement assessment battery for children. Percept Mot Skills. 2001;93:275-280.
18. Centraal Bureau Statistiek (Statistics Netherlands). Tourism, recreation, sports. Available from URL: http://www.cbs.nl [accessed January 26, 2006].
19. Vainionpaa L, Kovala T, Tolonen EU, et al. Vincristine therapy for children with acute lymphoblastic leukemia impairs conduction in the entire peripheral nerve. Pediatr Neurol. 1995;13:314-318.
20. Gaynon PS, Lustig RH. The use of glucocorticoids in acute lymphoblastic leukemia of childhood. Molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol. 1995; 17:1-12.
21. Thornton MJ, O'Sullivan G, Williams MP, Hughes PM. Avascular necrosis of bone following an intensified chemotherapy regimen including high dose steroids. Clin Radiol. 1997; 52:607-612.
22. Wei SY, Esmail AN, Bunin N, Dormans JP. Avascular necrosis in children with acute lymphoblastic leukemia. J Pediatr Orthop. 2000;20:331-335.
23. Shuper A, Stark B, Kornreich L, Cohen IJ, Avrahami G, Yaniv I. Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. Isr Med Assoc J. 2002;4:1050-1053.
24. Sanchez-Carpintero R, Narbona J, Lopez de Mesa R, Arbizu J, Sierrasesumaga L. Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol. 2001; 24:145-148.
25. Ruggiero A, Conter V, Milani M, et al. Intrathecal chemotherapy with antineoplastic agents in children. Paediatr Drugs. 2001;3:237-246.
26. Mattano LA Jr., Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol. 2000;18:3262-3272.
27. Strauss AJ, Su JT, Dalton VM, Gelber RD, Sallan SE, Silverman LB. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol. 2001;19:3066-3072.
28. Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev. 1994;20:191-214.
29. Shiraishi S, Le Quesne PM, Gajree T, Cavanagh JB. Morphometric effects of vincristine on nerve regeneration in the rat. J Neurol Sci. 1985;71:165-181.
30. Tanaka EM, Kirschner MW. Microtubule behavior in the growth cones of living neurons during axon elongation. J Cell Biol. 1991;115:345-363.
31. Tanaka E, Ho T, Kirschner MW. The role of microtubule dynamics in growth cone motility and axonal growth. J Cell Biol. 1995;128:139-155.
32. Lehtinen SS, Huuskonen UE, Harila-Saari AH, Tolonen EU, Vainionpaa L, Lanning BM. Motor nervous system impairment persists in long-term survivors of childhood acute lymphoblastic leukemia. Cancer. 2002;94:2466-2473.
33. Verstappen CC, Koeppen S, Heimans JJ, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology. 2005;64:1076-1077.
34. Mercuri E, Poulton J, Buck J, et al. Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A. Arch Dis Child. 1999;81:442-443.
35. Schiavetti A, Frascarelli M, Uccini S, Novelli A. Vincristine neuropathy: neurophysiological and genetic studies in a case of Wilms tumor. Pediatr Blood Cancer. 2004;43:606-609.